Transfusion-Transmitted Infection in Hemophilia in Developing Countries

ABSTRACT

Treatment of patients with bleeding disorders (especially those with hemophilia) with blood products has been associated with infections with blood-borne viruses. Of these, hepatitis B and C viruses (HBV and HCV, respectively) and the human immunodeficiency virus (HIV) have created major health problems. Although virus-inactivation procedures have virtually eliminated these viruses from newer factor concentrates since 1985, the risk remains in developing countries where there is no ready access to these concentrates. Although a few of these countries have established their own fractionation facilities and in others the respective governments make concentrates available, the large majority of countries still face the problems of blood-borne infections. HCV will invariably lead to liver damage and many hemophiliacs who were exposed to the HCV virus will succumb to cirrhosis. Only approximately 10% of hemophilic patients infected with HCV will clear the infection naturally. Coinfection with HIV shortens the life expectancy. The HIV epidemic in hemophiliacs began in the mid-1980s. Patients in developed countries were especially affected because they were predominantly treated with factor concentrates that were manufactured from thousands of blood donors. Hemophiliacs in developing countries have considerably less HIV infection, although it does exist and depends largely on the source of the plasma fractions. Progress has been made not only in the purification of factor concentrates, but also in the understanding of the HIV virus and in the development of antiretroviral treatment modalities. However, there are still several challenges in delivering antiretroviral treatment that must be addressed before the full impact of these transmitted infections is known.

KEYWORDS

Hemophilia - HBV - HCV - HIV - factor concentrates - antiretroviral treatment - developing countries

REFERENCES

• 1 Lee C A, Phillips A, Elford J et al.. The natural history of human immunodeficiency virus infection in a haemophilic cohort.  Br J Haematol. 1989;  73 228-234
• 2 Kernoff P B, Lee C A, Karayiannis P, Thomas H C. High risk of a non-A non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates effects of prophylactic immune serum globulin.  Br J Haematol. 1985;  60 469-479
• 3 The Economist . Could AIDS explode in India?.  Economist. 2004;  (April) 17
• 4 Mannucci P M. The choice of plasma-derived clotting factor concentrates.  Baillieres Clin Haematol. 1996;  9 273-290
• 5 Farrugia A. Safety and supply of haemophilia products: worldwide perspectives.  Haemophilia. 2004;  10 327-333
• 6 Yee T T, Cohen B J, Pasi K J, Lee C A. Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate.  Br J Haematol. 1996;  93 457-459
• 7 Burnouf T, Radosevich M. Reducing the risk of infection from plasma products; specific preventative strategies.  Blood Rev. 2000;  14 94-110
• 8 Srivastava A. Factor replacement therapy in haemophilia-are there models for developing countries?.  Haemophilia. 2003;  9 391-396
• 9 Bird A, Isarangkura P, Almagro D, Gonzaga A, Srivastava A. Factor concentrates for haemophiliacs in the developing world.  Haemophilia. 1998;  4 481-485
• 10 Chuansumrit A. Treatment of haemophilia in the developing countries.  Haemophilia. 2003;  9 387-390
• 11 Petersen I P, Bird A R. Small pool heat treated intermediate purity factor VIII concentrate. Montreal, Canada; World Federation of Haemophilia Monograph 1997 (April): 1-4
• 12 WFH Global Survey 2003 .World Federation of Haemophilia. Available at: http://www.wfh.org Accessed August 5, 2005
• 13 Choo Q L, Kuo G, Weiner A J et al.. Isolation of a C DNA done derived from a blood-borne non-A, non-B viral hepatitis genome.  Science. 1989;  244 359-362
• 14 Rosenberg W, Khakoo S. Epidemiology, natural history and pathophysiology. In: Pocket Reference to Hepatitis C Infection London; Science Press 2002
• 15 Mansour-Ghanaei F, Fallah M S, Shafaghi A et al.. Prevalence of hepatitis B and C seromarkers and abnormal liver function tests among hemophiliacs in Guilan (northern province of Iran).  Med Sci Monit. 2002;  8 797-800
• 16 Timan I S, Aulia D, Atmakusma D et al.. Some hematological problems in Indonesia.  Int J Hematol. 2002;  76(suppl 1) 286-290
• 17 Seme K, Poljak M, Begovac J et al.. Low prevalence of hepatitis C virus infection among human immunodeficiency virus type 1-infected individuals from Slovenia and Croatia.  Acta Virol. 2002;  46 91-94
• 18 Wharfe G, Smikle M, Dowe G et al.. Seroprevalence of hepatitis C virus in haemophiliacs in Jamacia.  Hum Antibodies. 2002;  11 61-64
• 19 Fontes E M, Amorim L, Carvalho S M, Farah M B. Hemophilia care in the state of Rio de Janeiro, Brazil.  Rev Panam Salud Publica. 2003;  13 124-128
• 20 Carmo R A, Oliveira G C, Guimaraes M D et al.. Hepatitis C virus infection among Brazilian hemophiliacs: a virological, clinical and epidemiological study.  Braz J Med Biol Res. 2002;  35 589-598
• 21 Barbosa A P, Martins R M, Teles S A et al.. Prevalence of hepatitis C virus infection among hemophiliacs central Brazil.  Mem Inst Oswaldo Cruz. 2002;  97 643-644 , errata August 30, 2002
• 22 Jarvis L M, Watson H G, McOmish F et al.. Frequent reinfection and reactivation of hepatitis C virus genotypes in multitransfused hemophiliacs.  J Infect Dis. 1994;  170 1018-1022
• 23 Jarvis L M, Ludlam C A, Simmonds P. Hepatitis C virus genotypes in multi-transfused individuals.  Haemophilia. 1995;  1(suppl 4) 3-7
• 24 Eyster M E, Sherman K E, Goedert J J, Katsoulidou A, Hatzakis A. Prevalence and changes in hepatitis C virus genotype among multitransfused persons with hemophilia. The Multicenter Hemophilia Cohort Study.  J Infect Dis. 1999;  179 1062-1069
• 25 Sheng L, Willems M, Peenlinck K, Vermylen J, Yap S H. Hepatitis C virus genotypes in Belgian haemophiliacs.  J Med Virol. 1995;  45 211-214
• 26 Suou T, Kawatani T, Nishikawa K et al.. High prevalence of hepatitis C virus genotype 1a in Japanese hemophiliacs.  Int Hepatol Commun. 1996;  4 301-304
• 27 Mauser-Bunschoten E P, Bresters D, Van Drimmelen A A et al.. Hepatitis C infection and viremia in Dutch hemophilia patients.  J Med Virol. 1995;  45 241-246
• 28 Yee T T, Griffoen A, Sabin C A, Dusheiko G, Lee C A. The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985.  Gut. 2000;  47 845-851
• 29 Franchini M, Rossetti G, Tagliferri A et al.. The natural history of chronic hepatitis C in a cohort of HIV negative Italian patients with hereditary bleeding disorders.  Blood. 2001;  98 1836-1841
• 30 Darby S C, Ewart D W, Giangrande P LF et al.. Mortality from liver cancer and liver disease in haemophilic men and boys in the UK given blood products contaminated with hepatitis C.  Lancet. 1997;  350 1425-1431
• 31 Wilde J T. HIV and HCV coinfection in haemophilia.  Haemophilia. 2004;  10 1-8
• 32 Ragni M V, Belle S H. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with haemophilia and hepatitis C virus infection.  J Infect Dis. 2001;  183 1112-1115
• 33 Quintana M, Villar A, Jimenez V et al.. Progression of HIV infection and mortality by hepatitis infection in patients with haemophilia over 20 years.  Haemophilia. 2003;  9 605-612
• 34 Eyster M E, Fried M W, Di Bisceglie A M, Goedert J J. Increasing hepatitis C virus RNA levels in haemphiliacs: relationship to human immunodefiency virus infection and liver disease.  Blood. 1994;  84 1020-1023
• 35 Fauci A S, Schnittman S M, Poli G, Koenig S, Pantaleo G. Immunopathogenetic mechanisms in human immunodeficiency virus (HIV) infection.  Ann Intern Med. 1991;  114 678-693
• 36 Sabin C A, Telfer P, Phillips A N, Bhagani S, Lee C A. The association between hepatitis C virus genotype and human immuno-deficiency virus disease progression in a cohort of haemophilic men.  J Infect Dis. 1997;  175 164-168
• 37 Centers for Disease Control . Pneumocystis carinii pneumonia among persons with haemophilia.  MMWR. 1982;  31 365
• 38 Bottiger B, Blombäck M, Berntorp E et al.. HIV-serology and Lymphocyte subsets in relation to therapy and clinical development in haemophiliacs.  Eur J Haematol. 1988;  41 459-466
• 39 Melbye M, Froebel K S, Madhok R et al.. HTLV-III seropositivity in European haemophiliacs receiving factor VIII concentrate imported from the USA.  Lancet. 1984;  2 1444-1446
• 40 Goedert J J, Sarngadharan M G, Eyster M E et al.. Antibodies reactive with human T cell leukemia viruses in the serum of haemophiliacs receiving factor VIII concentrate.  Blood. 1985;  65 492-495
• 41 Erfle V, Hehlmann R, Mellert W et al.. Prevalence of antibodies to HTLV-III in AIDS risk groups in West Germany.  Cancer Res. 1985;  45(suppl) 4627s-4629s
• 42 Darby S C, Rizza C R, Doll R et al.. Seropositivity for HIV and incidence of AIDS and AIDS related complex in UK haemophilics: report on behalf of the Directors of haemophilia centres in the UK.  BMJ. 1989;  298 1064-1068
• 43 Haemophilia Study Group . Haemophilia, HIV infection and blood transfusion in Belgium.  Acta Clin Belg. 1988;  39 44-48
• 44 Evensen S A, Ulstrup J, Skaug K et al.. HIV infection in Norwegian haemophiliacs treated with lyophilized cryoprecipitate from volunteer donors.  Eur J Haematol. 1987;  39 44-48
• 45 Rosendaal F R, Smit C, Varekamp I et al.. AIDS and haemophilia: a study among Dutch haemophiliacs on the psychological impact of the AIDS threat, the prevalence of HIV antibodies and the adoption of measures to prevent HIV infection.  Haemostasis. 1988;  18 73-82
• 46 Rasi V, Ikkala E, Myllyla G, Nevanlinna H R. Low prevalence of antibodies against human immunodeficiency virus in Finnish haemophiliacs.  Vox Sang. 1991;  60 159-161
• 47 Allain J P. Prevalence of HTLV-III/LAV antibodies in patients with haemophilia and their sexual partners in France.  N Engl J Med. 1986;  315 517-518
• 48 Singhvi A, Pulimood R B, John T J et al.. The prevalence of markers for hepatitis B and human immunodeficiency viruses, malarial parasites, and microfilaria in blood donors in a large hospital in south India.  J Trop Med Hyg. 1990;  93 178
• 49 Karimi M, Yarmohammadi H, Ardeshiri R, Yarmohammadi H. Inherited coagulation disorders in southern Iran.  Haemophilia. 2002;  8 740-744
• 50 Hosseinipour M C, Kazembe P N, Sanne I M, van der Horst C M. Challenges in delivering antiretroviral treatment in resource poor countries.  AIDS. 2002;  16(suppl 4) S177-187
• 51 Sherring A, Bergeron M, Mandy F. Comparison of two alternative CD4 T-cell enumerating methods suitable for laboratories with low volume immunophenotyping in resource-poor settings. Program and abstracts of the XIV International AIDS Conference July 7-12, 2002 Barcelona, Spain;
• 52 WHO .Scaling up antiretroviral therapy in resource limited settings: Guidelines for a public health approach: Executive summary. Geneva; World Health Organization 2002
• 53 Qazi S, Vareldzis B, Giaquinto C. HIV treatment for children: applying the 2002 WHO interim ARV treatment guidelines for resource poor settings. Program and abstracts or the XIV International AIDS Conference July 7-12, 2002 Barcelona, Spain;
• 54 Yeni P G, Hammer S M, Carpenter C C et al.. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.  JAMA. 2002;  288 222-235
• 55 Paterson D L, Swindells S, Mohr J et al.. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.  Ann Intern Med. 2000;  133 21-30
• 56 Adje C, Cheingsong R, Roels T H et al.. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Cote d'Lvoire.  J Acquir Immune Defic Syndr. 2001;  26 501-506
• 57 Vergne L, Malonga-Mouellet G, Mistoul I et al.. Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines in ARV use and HIV-1 drug resistance monitoring in developing countries.  J Acquir Immune Defic Syndr. 2002;  29 165-168
• 58 James JS. Treatment in developing countries: new UNAIDS pilot program.  AIDS Treat News. 1997;  283 7
• 59 Weidle P J, Malamba S, Mwebaze R et al.. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients response, survival, and drug resistance.  Lancet. 2002;  360 34-40
• 60 From Durban to Barcelona .Overcoming the treatment deficit. Available at: http://www.doctorswithoutborders.org/publications/reports/2002/fdtb_07-2002.pdf Accessed August 5, 2005